301520 万邦医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.73112.03934.98142.65272.200
总资产报酬率 ROA (%)3.53311.09128.69233.81854.367
投入资产回报率 ROIC (%)3.66211.71232.52337.69660.142

边际利润分析
销售毛利率 (%)46.10948.93850.38252.71255.787
营业利润率 (%)30.49734.81740.67941.30042.726
息税前利润/营业总收入 (%)30.66833.65442.28044.48945.044
净利润/营业总收入 (%)29.39631.62437.86138.78439.183

收益指标分析
经营活动净收益/利润总额(%)76.08792.77088.69990.27291.023
价值变动净收益/利润总额(%)22.3525.1982.8571.9651.905
营业外收支净额/利润总额(%)4.1340.5344.5557.5765.273

偿债能力分析
流动比率 (X)20.34020.3514.3875.1053.702
速动比率 (X)20.32520.3414.3805.1013.693
资产负债率 (%)5.4385.21718.03817.89324.699
带息债务/全部投入资本 (%)0.6580.9464.1585.41613.882
股东权益/带息债务 (%)14,928.16010,378.5712,252.2061,699.051600.072
股东权益/负债合计 (%)1,738.9841,816.848454.373458.873304.875
利息保障倍数 (X)-26.802-24.926-123.982-226.532-750.687

营运能力分析
应收账款周转天数 (天)53.05245.53033.31918.81918.712
存货周转天数 (天)1.5061.1450.8681.0052.211